BioSpace News Archive

Oncotelic Therapeutics, Inc, unveils a state-of-the-art GMP Manufacturing Plant, a significant stride in biopharmaceutical innovation, through its joint venture Sapu Biosciences LLC.

Waters Corporation announced that its Board of Directors has been named 2024 “Public Company Board of the Year” by the National Association of Corporate Directors New England Chapter.

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of best-in-class IL-2 therapeutics, today announced plans to initiate the Phase 2 portion of its Phase 1/2 clinical trial of AU-007 in patients with unresectable locally advanced or metastatic solid tumor cancers of the skin and kidney.

Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8.

Jeff Wolf, CEO of NightHawk, commented, “We are generating strong interest in our CDMO services, given our state-of-the-art facility and the industry-wide lack of available capacity for large molecule manufacturing.

Starton Therapeutics Inc., (the “Company”) today announced that Pedro Lichtinger, Chairman & Chief Executive Officer of Starton Therapeutics, will present a company overview including an update on interim data of its ongoing STAR-LLD Phase 1B continuous delivery of lenalidomide.

iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, announced the expansion of its sales leadership with the addition of Peter Graham, as Senior Vice President, North American Sales and a role change for Bill Keyes to Senior Vice President, Global Sales Operations, both effective immediately.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company) today announced positive preclinical results from an in vivo study evaluating the antibacterial efficacy of its lead synthetic anti-infective candidate, RECCE® 327 (R327), against Neisseria gonorrhoeae (N. gonorrhoeae) in a mouse vaginal infection model.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 10:30 a.m. PT (1:30 p.m. ET).